192 related articles for article (PubMed ID: 20213094)
21. Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.
Suzuki Y; Saito Y; Terao M; Terada M; Morioka T; Tsuda B; Okamura T; Niikura N; Tokuda Y
Tokai J Exp Clin Med; 2010 Dec; 35(4):148-51. PubMed ID: 21319046
[TBL] [Abstract][Full Text] [Related]
22. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
Creedon H; Byron A; Main J; Hayward L; Klinowska T; Brunton VG
Biochem Soc Trans; 2014 Aug; 42(4):822-30. PubMed ID: 25109964
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab for advanced bladder cancer.
Siva N
Lancet Oncol; 2007 Jul; 8(7):576. PubMed ID: 17668481
[No Abstract] [Full Text] [Related]
24. Inhibitors of HER2/neu (erbB-2) signal transduction.
Arteaga CL; Chinratanalab W; Carter MB
Semin Oncol; 2001 Dec; 28(6 Suppl 18):30-5. PubMed ID: 11774203
[TBL] [Abstract][Full Text] [Related]
25. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Jo Chien A; Rugo HS
Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
[No Abstract] [Full Text] [Related]
26. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
Eniu A
J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
[TBL] [Abstract][Full Text] [Related]
27. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
Moulder SL
Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S30-40. PubMed ID: 20805063
[TBL] [Abstract][Full Text] [Related]
28. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
29. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.
Brandes AA; Franceschi E; Tosoni A; Degli Esposti R
Expert Rev Anticancer Ther; 2010 Feb; 10(2):179-84. PubMed ID: 20131994
[TBL] [Abstract][Full Text] [Related]
31. Trastuzumab for gastric cancer.
Meza-Junco J; Au HJ; Sawyer MB
Expert Opin Biol Ther; 2009 Dec; 9(12):1543-51. PubMed ID: 19916733
[TBL] [Abstract][Full Text] [Related]
32. [Targeting ErbB receptors in breast cancer].
Fumoleau P; Campone M; Coudert B; Mayer F; Favier L; Ferrant E
Bull Cancer; 2007; 94(7 Suppl):F147-70. PubMed ID: 17964992
[TBL] [Abstract][Full Text] [Related]
33. Lapatinib for breast cancer: a review of the current literature.
MacFarlane RJ; Gelmon KA
Expert Opin Drug Saf; 2011 Jan; 10(1):109-21. PubMed ID: 21091041
[TBL] [Abstract][Full Text] [Related]
34. EGFR and HER-2 antagonists in breast cancer.
O'Donovan N; Crown J
Anticancer Res; 2007; 27(3A):1285-94. PubMed ID: 17593621
[TBL] [Abstract][Full Text] [Related]
35. HER-2-targeted therapy: lessons learned and future directions.
Nahta R; Esteva FJ
Clin Cancer Res; 2003 Nov; 9(14):5078-84. PubMed ID: 14613984
[TBL] [Abstract][Full Text] [Related]
36. Targeted therapy for gastric cancer--current status.
Kulig J; Kołodziejczyk P; Kulig P; Legutko J
J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
[TBL] [Abstract][Full Text] [Related]
37. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
39. [Breast cancer and Her-2].
Hatake K
Nihon Rinsho; 2007 Jun; 65 Suppl 6():87-94. PubMed ID: 17682144
[No Abstract] [Full Text] [Related]
40. Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.
Berghoff AS; Bago-Horvath Z; Dubsky P; Rudas M; Pluschnig U; Wiltschke C; Gnant M; Steger GG; Zielinski CC; Bartsch R
Breast J; 2013; 19(2):149-55. PubMed ID: 23350584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
